{"id":23559,"date":"2025-11-19T09:15:01","date_gmt":"2025-11-19T14:15:01","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&#038;p=23559"},"modified":"2026-04-21T11:10:23","modified_gmt":"2026-04-21T15:10:23","slug":"outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/","title":{"rendered":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario"},"content":{"rendered":"<p>The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients with MCL from 2005 to 2020. We defined transplant-eligible (TE) patients as those aged &lt;70 years who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP\/R-DHAP (rituximab, dexamethasone, high-dose cytarabine and dexamethasone) and transplant-ineligible (TI) patients as those aged \u226570 years and treated with bendamustine-rituximab (BR) or other chemoimmunotherapy regimens. The primary outcome was 5-year overall survival (OS), and secondary outcomes included toxicities and health care use. We identified 426 TE patients, of whom 254 received R-CHOP and 172 received R-CHOP\/R-DHAP. More patients who received R-CHOP\/R-DHAP also received an autologous stem cell transplant (ASCT). The 5-year OS for patients treated with R-CHOP\/R-DHAP was 70.5% compared with 62.0% for patients treated with R-CHOP, regardless of transplant status. R-CHOP\/R-DHAP had more hospital admissions for fever, infection, neutropenia, and renal toxicity. TI patients received BR (n = 303) or historical regimens (n = 189). BR was associated with lower mortality. After adjustment, maintenance rituximab was associated with significantly lower mortality (hazard ratio, 0.33; 95% confidence interval, 0.24-0.44). More patients treated with BR had hospital admissions for febrile neutropenia. In this large population-based study, R-CHOP\/R-DHAP before ASCT showed a trend toward improved 5-year OS. BR did not result in superior OS after adjustment, suggesting other regimens followed by rituximab maintenance may be reasonable.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients with MCL from 2005 to 2020. We defined transplant-eligible (TE) patients as those aged &lt;70 years who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP\/R-DHAP (rituximab, dexamethasone, high-dose cytarabine and dexamethasone) and [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,54,56],"migration-helper-qa-sample-set":[],"class_list":["post-23559","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-organ-transplantation-and-donation","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Suleman A, Ante Z, Liu N, Crump M, Chan KKW, Cheung MC, Prica A. <em>Blood Neoplasia<\/em>. 2026; 3(2): 100184. Epub 19 Nov 2025.","source_url":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100184","ices_scientist":[1185,1193],"site":[6733],"research_program":[6741],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario<\/title>\n<meta name=\"description\" content=\"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario\" \/>\n<meta property=\"og:description\" content=\"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T15:10:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\\\/\",\"name\":\"ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2025-11-19T14:15:01+00:00\",\"dateModified\":\"2026-04-21T15:10:23+00:00\",\"description\":\"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","description":"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","og_description":"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2026-04-21T15:10:23+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/","name":"ICES | Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2025-11-19T14:15:01+00:00","dateModified":"2026-04-21T15:10:23+00:00","description":"The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/23559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1193"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1185"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=23559"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=23559"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=23559"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=23559"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=23559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}